The incidence of atrial fibrillation in the aging population continues to increase in frequency and predisposes patients to an increased risk for stroke. Assessment of risk for stroke is a significant and independent risk factor for stroke.
An important element weighing the risk of bleeding on anticoagulation is to assess it along with the risk of morbidity and mortality from stroke. The HASBLED Scale describes patient characteristics that affect bleeding risk.
The selection of the appropriate medical therapy requires a sound knowledge about the characteristics of these medications which include warfarin and newer medications such as dabigatran etexilate, rivaroxaban, apixaban, and edoxaban.
Consistency in medication compliance, diet, and activities are critical elements in a comprehensive care plan. An effective plan of care minimizes stroke risk while not creating a significant risk of bleeding.
TEAM-A is an innovative educational collaboration among ten organizations committed to improving patient outcomes through clinician education:
The TEAM-A initiative is supported by an independent medical educational grant from the Bristol-Myers Squibb/Pfizer Pharmaceuticals Partnership.
Selected TEAM-A activities are supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.